Glucient Sr

Glucient Sr is a prescription oral medication containing metformin hydrochloride, a biguanide antidiabetic agent, marketed in the European Union. It is formulated for systemic absorption and is used to improve glycemic control in adults with type 2 diabetes mellitus. The product does not contain additional active ingredients and is supplied as tablets (strength not specified). Glucient Sr is prescribed by healthcare professionals and should be taken according to individual treatment plans.

Glucient Sr is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment strategy.

- As monotherapy in patients whose diet and exercise alone are insufficient to achieve glycemic targets. - In combination with other oral antidiabetic agents when additional glucose lowering is needed. - As an adjunct to insulin therapy to reduce the required insulin dose. - To improve fasting plasma glucose and HbA1c levels in conjunction with lifestyle modifications.

The safety profile of metformin hydrochloride includes both common and less frequent adverse events.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Mild headache. - Decreased appetite.

Serious: - Lactic acidosis, a rare but life‑threatening condition. - Severe skin reactions including Stevens‑Johnson syndrome. - Hepatotoxicity manifested by jaundice. - Persistent vomiting leading to dehydration.

Clinicians should evaluate several factors before initiating Glucient Sr to ensure safe use.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Review hepatic status, as liver disease may increase risk of lactic acidosis. - Monitor for signs of hypoxia or heart failure, which can predispose to serious metabolic complications. - Use caution in elderly patients due to altered drug clearance. - Avoid use in patients with a history of alcohol abuse or acute illness that may affect kidney function.

Metformin hydrochloride may interact with other medicines, affecting its efficacy or safety.

Avoid: - Concurrent use with iodinated contrast agents without appropriate discontinuation. - Co‑administration with potent inhibitors of renal tubular secretion such as cimetidine. - Use with other biguanides (e.g., phenformin) due to additive risk of lactic acidosis.

Use with caution: - Combination with insulin or sulfonylureas, which may increase risk of hypoglycemia. - Concomitant use of corticosteroids or thiazide diuretics that can raise blood glucose levels. - Administration with alcohol, which may potentiate lactic acidosis.